SAN

81.75

-0.05%↓

MRK1

120.55

+1.64%↑

SHL.DE

44.59

+0.36%↑

ARGX

722.6

-1.23%↓

FRE

48.51

+1.27%↑

SAN

81.75

-0.05%↓

MRK1

120.55

+1.64%↑

SHL.DE

44.59

+0.36%↑

ARGX

722.6

-1.23%↓

FRE

48.51

+1.27%↑

SAN

81.75

-0.05%↓

MRK1

120.55

+1.64%↑

SHL.DE

44.59

+0.36%↑

ARGX

722.6

-1.23%↓

FRE

48.51

+1.27%↑

SAN

81.75

-0.05%↓

MRK1

120.55

+1.64%↑

SHL.DE

44.59

+0.36%↑

ARGX

722.6

-1.23%↓

FRE

48.51

+1.27%↑

SAN

81.75

-0.05%↓

MRK1

120.55

+1.64%↑

SHL.DE

44.59

+0.36%↑

ARGX

722.6

-1.23%↓

FRE

48.51

+1.27%↑

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Open

1.438 0.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.417

Max

1.466

Belangrijke statistieken
By Trading Economics
Inkomsten	2.9M 7.5M
Verkoop	4.1M 97M
EPS	0.009
Winstmarge	7.758
Werknemers	404

Marktinformatie
By TradingEconomics
Marktkapitalisatie	768K 998M
Vorige openingsprijs	0.46
Vorige sluitingsprijs	1.438

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 dec 2025, 23:54 UTC

Belangrijke Marktbewegers

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22 dec 2025, 19:08 UTC

Acquisities, Fusies, Overnames

Correction to Alphabet to Buy Intersect Article

22 dec 2025, 17:21 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22 dec 2025, 16:46 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75 Billion in Cash

22 dec 2025, 23:50 UTC

Marktinformatie

Nikkei May Decline as Yen Rebounds -- Market Talk

22 dec 2025, 23:42 UTC

Marktinformatie

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22 dec 2025, 22:31 UTC

Winsten

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22 dec 2025, 22:30 UTC

Winsten

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 21:37 UTC

Acquisities, Fusies, Overnames

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22 dec 2025, 21:36 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn to Acquire Prospective Package From Tempest Minerals

22 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22 dec 2025, 20:52 UTC

Acquisities, Fusies, Overnames

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22 dec 2025, 20:09 UTC

Marktinformatie

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22 dec 2025, 19:56 UTC

Marktinformatie

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22 dec 2025, 19:49 UTC

Acquisities, Fusies, Overnames

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22 dec 2025, 19:23 UTC

Marktinformatie

Mexico's Inflation Seen Easing in Early December -- Market Talk

22 dec 2025, 19:23 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 dec 2025, 19:02 UTC

Marktinformatie

Precious Metals Climb to New Heights -- Market Talk

22 dec 2025, 18:45 UTC

Marktinformatie

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22 dec 2025, 18:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22 dec 2025, 18:23 UTC

Acquisities, Fusies, Overnames

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22 dec 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

22 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

22 dec 2025, 17:06 UTC

Acquisities, Fusies, Overnames

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.